Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Biotechs Cut Staff After Drug Setbacks

June 4, 2007 | A version of this story appeared in Volume 85, Issue 23

VaxGen is shedding 25% of its workforce, or 20 employees, after discontinuing further development of its recombinant anthrax vaccine. This is the second wave of layoffs at the troubled biotech firm, which cut more than half its workforce in January after the Department of Health & Human Services canceled a contract for 75 million doses of the anthrax vaccine. VaxGen says it is now looking for a partner to continue the vaccine program. Separately, AtheroGenics is cutting about half its staff to 67 employees in order to focus on commercializing its heart disease drug, AGI-1067. AstraZeneca ended its partnership for AGI-1067 in April after the drug came up short in a Phase III trial.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.